A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Substudy
This study is testing new combinations of medications to treat a fast-growing blood cancer called acute myeloid leukemia in older or medically unfit adults. Researchers want to see if adding a targeted drug called gilteritinib to standard treatments helps patients achieve a better and deeper remission.
You may be able to join if you are 60 years or older, or under 60 if your doctor feels milder therapy is safer for you, with a newly diagnosed specific type of leukemia. You must also have a certain genetic mutation known as FLT3 and have not received prior treatment for this condition.
Participants will be randomly assigned to receive either the usual combination of drugs or the new three-drug combination to help fight the cancer. You will also provide blood and bone marrow samples so doctors can closely monitor how well the treatment is working.
This study is currently recruiting patients at medical centers in locations such as Birmingham, Alabama, and Tucson, Arizona. Your care team will guide you through the specific clinic visits and tests needed during the trial.
- 1Tests a new three-drug combination against the standard treatment for a specific type of leukemia
- 2Open to adults aged 60 and older, or younger adults who need a gentler treatment approach
- 3Involves regular monitoring through blood and bone marrow tests to track your progress
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.